trial

The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes

NCTId NCT01832766
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1, Phase 2 · Terminated
Enrollment 13 (actual)
Sponsored by University of Colorado, Denver
Primary completion 2010-05
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1, Phase 2
Status
Terminated
Enrollment
13 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2005-06
Primary completion
2010-05
Eligibility
ALL · 18 Years · 50 Years

Interventions & indications

Drugs
Dronabinol

Sponsors

University of Colorado, DenverLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator

Investigators

1
Lynn Johnson, Pharm DPrincipal Investigator

Sites

1 total
Aurora, United States

Linked catalysts

1
The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsych — primary completion2010-05

Facts & assertions

4 sourced
Enrollment
13
Phase
PHASE1,PHASE2
Primary Completion Date
2010-05
Status
TERMINATED
relationships
The graph out of here
drug
Dronabinol
drug
lead_sponsor
University of Colorado, Denver
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
indication
Schizophrenia
indication
Schizophrenia
indication
Marijuana Abuse
indication
investigator
Lynn Johnson, Pharm D
person